India to regulate device and Dx pricing
This article was originally published in Clinica
Draft legislation to regulate the price of medical devices and diagnostic kits in India will soon be introduced to parliament to help reduce the cost of healthcare. The legislation aims to increase the level of competition between medtech companies through measures such as ensuring that all devices and kits are ISO certified and that they adhere to preset standards. The proposed regulation was announced by Kapil Sibal, the union minister of science and technology, on December 15. He was reported to have said that India aspires to achieve the lowest cost healthcare in the world, and he called for the setting up of more medical colleges and institutes for nurses and paramedics. He also said that India should find its own model of healthcare that would suit the pockets of its citizens; he cautioned against emulating the systems of developed countries that would not work for India as the majority of people, including the swelling middleclass, cannot afford rising healthcare costs. Medical technologies are said to constitute 30-40% of health costs in India.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.